HOME > TOP STORIES
TOP STORIES
-
BUSINESS Mylan Japan Offers Severance Package for 110 Sales Reps
March 29, 2016
-
BUSINESS Torii Looks to Ramp Up Sales in Allergen Sector, Expand Indications for Sublingual Therapies
March 28, 2016
-
BUSINESS MSD Going Full Out for Sakigake-Designated Pembrolizumab, Poised to Bolster Oncology Force
March 25, 2016
-
BUSINESS Hengrui to Apply for Sakigake Designation; Develop New Drugs Alongside Generics in Japan
March 24, 2016
-
ACADEMIA Positioning of Abraxane and Anti-PD-1 Antibodies Will Be Focus of Interest in Revised Guidelines for Gastric Cancer
March 23, 2016
-
BUSINESS Jitsubo Aims to Launch Peptide Generic Drugs Using Its Unique Technologies
March 22, 2016
-
ORGANIZATION FPMAJ Braced for Thorny Path Ahead Even If Sales Tax Postponed, Revenue Falls Would Weigh on Industry: Chief
March 18, 2016
-
ORGANIZATION Discuss Role of Drugs in Overall Social Security System: Full Interview with FPMAJ Pricing Affairs Chief
March 18, 2016
-
REGULATORY Whether to Draw Line between 15 Billion and 100 Billion Yen Sales Thresholds for Re-Pricing Will Hold Key: Kamoya, Nakai
March 17, 2016
-
ACADEMIA It’s Time to Discuss Restart of HPV Vaccine Promotion, Panel Chief Says as Personal View
March 16, 2016
-
REGULATORY Sales Thresholds for Re-Pricing Rule to Be Key Point of Future Discussions: MHLW Pharma Management Director
March 15, 2016
-
REGULATORY No Licensing Deal Clinched for First AMED-Backed Drug Seed
March 14, 2016
-
BUSINESS Ono Beefing Up Organization for Safe Use of Opdivo, Eyes Larger Cancer Sales Force
March 11, 2016
-
ORGANIZATION “Huge-Seller” Re-Pricing Eroding Predictability of Japanese System: FPMAJ’s Kamoya
March 10, 2016
-
BUSINESS Re-Pricing, Z2, Deferred Price Cuts Hammering Mainstay Drugs, Otsuka Sees Double-Digit Reductions for Top 5 Sellers: Tally
March 9, 2016
-
BUSINESS Kyowa Kirin Expects to Double Sales Force in US to Build Independent Marketing System; Anticipates Launch of Parkinson’s Drug in 2018
March 8, 2016
-
BUSINESS Drug Price Cut to Net Out at 5.5% for Chugai, Gilead to Suffer 31.65% in Full: Jiho Tally
March 7, 2016
-
REGULATORY Sovaldi, Harvoni Face 31.7% Price Cut under “Huge Seller” Re-Pricing: MHLW
March 4, 2016
-
REGULATORY FY2016 NHI Pricing Reform to Bring “1 Victory, 1 Defeat, 1 Draw” for Industry: MHLW Official
March 3, 2016
-
BUSINESS Sakigake: Now and Future (4) - MSD’s Anti-PD-1 Antibody Gets Sakigake Designation for Gastric Cancer, While Opdivo also Under Development for Same Indication
March 2, 2016
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…